Center of Research on Obesity and Cardiovascular Disease

肥胖与心血管疾病研究中心

• 批准号: 10458562
• 负责人: Lisa A Cassis
• 金额: $ 114.75万
• 依托单位: UNIVERSITY OF KENTUCKY
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-08-01 至 2024-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10458562
• 关键词: Adipose tissue; Advisory Committees; Aging; Alzheimer' s Disease; Area; Award; Basic Science; Body Composition; Cardiovascular Diseases; Cardiovascular system; Center for Translational Science Activities; Centers of Research Excellence; Chronic Disease; Clinical Research; Clinical Sciences; Core Facility; Death Rate; Development; Diabetes Mellitus; Disease; Equipment; Etiology; Evaluation; Extramural Activities; Fostering; Funding; Gills; Goals; Growth; High Prevalence; Hypertension; Infrastructure; Institutes; Institution; Kentucky; Limb structure; Link; Lipids; Malignant Neoplasms; Mass Spectrum Analysis; Mentors; Morphology; Mus; Neurodegenerative Disorders; Neurosciences; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Pathology; Phase; Physicians; Pilot Projects; Prevalence; Publications; Publishing; Request for Applications; Research; Research Infrastructure; Research Personnel; Research Support; Risk; Risk Factors; Scientist; Services; Strategic Planning; System; Technology; Tissues; Translating; Translational Research; United States National Institutes of Health; Universities; cancer research center director; cardiovascular risk factor; clinical care; clinical center; comorbidity; dietary; energy balance; experience; health disparity; human disease; improved; lipidomics; obesity development; programs; research facility; small molecule; success; targeted treatment; therapy development; voucher

Phase III of the Center for Biomedical Research Excellence (COBRE) on Obesity and Cardiovascular Diseases (COCVD) will further develop and expand upon obesity as an underlying risk factor for the development of cardiovascular diseases, type 2 diabetes, cancer and neurodegenerative diseases. Each of these diseases are rampant in Kentucky, and obesity has been identified as a contributing risk factor for each condition. For Phase III of the COCVD, we will transition the research core facilities developed during Phase I and II of this program to independence. We will also support pilot project studies that include obesity as a risk factor for disease development. We have experienced considerable success, having supported 23 junior investigators and 21 pilot project investigators who generated $52 million in extramural funding and published more than 500 scholarly publications. Collectively, our team has published more than 280 scholarly articles that directly cite COCVD support. We developed an analytical core that provides services in lipidomics and other small molecules, a pathology core that provides specialized services to quantify adipose and other tissue morphology, and an energy balance and body composition core that is not duplicated in capacity across the institution or the Commonwealth. During Phase III of the COCVD, we will transition each core to self- sustaining capacity and upgrade core equipment and use by continuing to provide high quality specialized services, and by expanding core capabilities through provision of additional services that relate obesity to other diseases (e.g., cancer). Transition to independence of COCVD cores will be facilitated by use of a voucher system to promote core use. We will also continue our strong tradition of pilot project funding, which will be expanded to include studies that focus on obesity as an underlying risk factor for not only cardiovascular diseases, but also type 2 diabetes, cancer and neurodegenerative diseases. These areas have been designated as areas of strength across the institution (as each disease is a health disparity experienced by Kentuckians), and are designated for growth within a new research facility that will focus on Kentucky's health disparities. The Administrative Core will oversee all administrative functions of the COCVD and in conjunction with the Program Coordinator and the Scientific Internal Advisory Committee will serve as the operational limb of the Center. An External Advisory Committee, composed of experts in related fields, will provide ongoing assessment and evaluation of the Center. Institutional commitment continues to be outstanding and is supplemented by strong evidence of programmatic growth of direct relevance to this Phase III COCVD.

生物医学研究中心卓越和心血管的第三阶段 疾病（COCVD）将进一步发展并扩大肥胖症，作为作为该肥胖的潜在危险因素 心血管疾病，2型糖尿病，癌症和神经退行性疾病的发展。每个 这些疾病在肯塔基州猖ramp，肥胖已被确定为每种疾病的危险因素 健康）状况。对于COCVD的第三阶段，我们将转变在第一阶段开发的研究核心设施 和该计划的II独立。我们还将支持包括肥胖为风险在内的试点项目研究 疾病发展因素。我们已经获得了很大的成功，并支持了23名初级 调查人员和21个飞行员项目调查人员产生了5200万美元的校外资金并出版了 超过500个学术出版物。总体而言，我们的团队发表了280多种学术文章 直接引用COCVD支持。我们开发了一个分析核心，该核心提供脂肪责任学的服务和 其他小分子，一种可提供专业服务来量化脂肪和其他组织的病理核心 形态学以及能量平衡和身体成分核心在整个范围内都没有重复 机构或英联邦。在COCVD的第三阶段，我们将每个核心转变为自我 维持容量和升级核心设备，并通过继续提供高质量的专业化 服务，以及通过提供将肥胖与其他服务相关的其他服务扩大核心功能 疾病（例如癌症）。过渡到COCVD核心的独立性将通过使用优惠券来促进 促进核心使用的系统。我们还将继续我们强大的飞行员项目资金传统，这将是 扩展到包括将肥胖作为作为心血管的潜在危险因素的研究 疾病，但还包括2种糖尿病，癌症和神经退行性疾病。这些领域已经 指定为整个机构的优势领域（每种疾病都是健康差异 肯塔基州），并被指定为新的研究机构的增长，该研究机构将重点介绍肯塔基州的健康 差异。管理核心将监督COCVD的所有管理功能，并结合使用 与计划协调员和科学内部咨询委员会一起，将作为运营肢体 中心。由相关领域专家组成的外部咨询委员会将提供持续的 中心的评估和评估。机构承诺仍然是杰出的，并且是 补充了与该阶段III COCVD直接相关性的有力证据。

项目成果

Monosomy X in Female Mice Influences the Regional Formation and Augments the Severity of Angiotensin II-Induced Aortopathies.

• DOI: 10.1161/atvbaha.120.314407
• 发表时间: 2021-01
• 期刊: Arteriosclerosis, thrombosis, and vascular biology
• 作者: AlSiraj Y;Thatcher SE;Blalock E;Saintilnord WN;Daugherty A;Lu HS;Luo W;Shen YH;LeMaire SA;Arnold AP;Cassis LA
• 通讯作者: Cassis LA

Inducible Depletion of Calpain-2 Mitigates Abdominal Aortic Aneurysm in Mice.

• DOI: 10.1161/atvbaha.120.315546
• 发表时间: 2021-05-05
• 期刊: Arteriosclerosis, thrombosis, and vascular biology
• 作者: Muniappan L;Okuyama M;Javidan A;Thiagarajan D;Jiang W;Moorleghen JJ;Yang L;Balakrishnan A;Howatt DA;Uchida HA;Saido TC;Subramanian V
• 通讯作者: Subramanian V

A Novel Role of Claudin-5 in Prevention of Mitochondrial Fission Against Ischemic/Hypoxic Stress in Cardiomyocytes.

• DOI: 10.1016/j.cjca.2021.03.021
• 发表时间: 2021-10
• 期刊: The Canadian journal of cardiology
• 作者: Luo T;Liu H;Chen B;Liu H;Abdel-Latif A;Kitakaze M;Wang X;Wu Y;Chou D;Kim JK
• 通讯作者: Kim JK

Dennd5b-Deficient Mice are Resistant to PCSK9-Induced Hypercholesterolemia and Diet-Induced Hepatic Steatosis.

• DOI: 10.1016/j.jlr.2022.100296
• 发表时间: 2022-12
• 期刊: JOURNAL OF LIPID RESEARCH
• 影响因子: 6.5
• 作者: Mobilia, Maura;Whitus, Callie;Karakashian, Alexander;Lu, Hong S.;Daugherty, Alan;Gordon, Scott M.
• 通讯作者: Gordon, Scott M.

De Novo Crohn's Disease Diagnosed in the Setting of Acute SARS-Cov-2 Infection Requiring Escalation of Infliximab Therapy Guided by Personalized Pharmacokinetics.

在急性 SARS-Cov-2 感染的情况下诊断出新发克罗恩病，需要在个性化药代动力学指导下升级英夫利昔单抗治疗。

• DOI: 10.26502/jppch.74050172
• 发表时间: 2024
• 期刊: Journal of pediatrics, perinatology and child health
• 作者: Romo,MartinVarea;Acharya,Kishor;Shelman,NathanR;Minar,Phillip;Denson,LeeA;Softic,Samir
• 通讯作者: Softic,Samir